Ilex Medical (ILX) - Net Assets
Based on the latest financial reports, Ilex Medical (ILX) has net assets worth ILA666.36 Million ILA (≈ $1.79 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA971.24 Million ≈ $2.60 Million USD) and total liabilities (ILA304.88 Million ≈ $817.38K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ILX PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA666.36 Million |
| % of Total Assets | 68.61% |
| Annual Growth Rate | 11.39% |
| 5-Year Change | 18.96% |
| 10-Year Change | 180.04% |
| Growth Volatility | 32.47 |
Ilex Medical - Net Assets Trend (2008–2025)
This chart illustrates how Ilex Medical's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Ilex Medical.
Annual Net Assets for Ilex Medical (2008–2025)
The table below shows the annual net assets of Ilex Medical from 2008 to 2025. Also explore Ilex Medical annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ILA684.71 Million ≈ $1.84 Million |
+5.91% |
| 2024-12-31 | ILA646.49 Million ≈ $1.73 Million |
+3.69% |
| 2023-12-31 | ILA623.51 Million ≈ $1.67 Million |
+1.70% |
| 2022-12-31 | ILA613.10 Million ≈ $1.64 Million |
+6.52% |
| 2021-12-31 | ILA575.57 Million ≈ $1.54 Million |
+29.77% |
| 2020-12-31 | ILA443.54 Million ≈ $1.19 Million |
+37.12% |
| 2019-12-31 | ILA323.48 Million ≈ $867.23K |
+10.22% |
| 2018-12-31 | ILA293.49 Million ≈ $786.83K |
+10.27% |
| 2017-12-31 | ILA266.15 Million ≈ $713.53K |
+8.85% |
| 2016-12-31 | ILA244.51 Million ≈ $655.52K |
+8.19% |
| 2015-12-31 | ILA225.99 Million ≈ $605.87K |
+10.45% |
| 2014-12-31 | ILA204.60 Million ≈ $548.53K |
-4.56% |
| 2013-12-31 | ILA214.38 Million ≈ $574.74K |
-17.53% |
| 2012-12-31 | ILA259.96 Million ≈ $696.93K |
-8.14% |
| 2011-12-31 | ILA282.99 Million ≈ $758.68K |
+134.26% |
| 2010-12-31 | ILA120.80 Million ≈ $323.87K |
-5.12% |
| 2009-12-31 | ILA127.32 Million ≈ $341.33K |
+16.33% |
| 2008-12-31 | ILA109.44 Million ≈ $293.42K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ilex Medical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 566.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ILA610.80 Million | 89.20% |
| Common Stock | ILA12.48 Million | 1.82% |
| Other Comprehensive Income | ILA-79.85 Million | -11.66% |
| Other Components | ILA141.29 Million | 20.64% |
| Total Equity | ILA684.71 Million | 100.00% |
Ilex Medical Competitors by Market Cap
The table below lists competitors of Ilex Medical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
King Core Electronics Inc
TW:6155
|
$154.19 Million |
|
KANGWON Co. Ltd
KQ:114190
|
$154.19 Million |
|
Cystech Electronics Corp
TWO:6651
|
$154.25 Million |
|
Calin Technology Co Ltd
TW:4976
|
$154.26 Million |
|
Kizilbuk Gayrimenkul Yatirim Ortakligi AS
IS:KZBGY
|
$154.09 Million |
|
Elanor Commercial Property Fund
AU:ECF
|
$154.07 Million |
|
ANDHRA PAPER LIMITED
NSE:ANDHRAPAP
|
$154.06 Million |
|
Mendelson Infrastructures and Industries Ltd
TA:MNIN
|
$154.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ilex Medical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 646,487,000 to 684,714,000, a change of 38,227,000 (5.9%).
- Net income of 55,555,000 contributed positively to equity growth.
- Dividend payments of 13,643,000 reduced retained earnings.
- Other comprehensive income decreased equity by 3,995,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA55.55 Million | +8.11% |
| Dividends Paid | ILA13.64 Million | -1.99% |
| Other Comprehensive Income | ILA-4.00 Million | -0.58% |
| Other Changes | ILA310.00K | +0.05% |
| Total Change | ILA- | 5.91% |
Book Value vs Market Value Analysis
This analysis compares Ilex Medical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 84.14x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 595.57x to 84.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | ILA8.63 | ILA5138.00 | x |
| 2014-12-31 | ILA9.16 | ILA5138.00 | x |
| 2015-12-31 | ILA11.93 | ILA5138.00 | x |
| 2016-12-31 | ILA14.06 | ILA5138.00 | x |
| 2017-12-31 | ILA16.18 | ILA5138.00 | x |
| 2018-12-31 | ILA18.92 | ILA5138.00 | x |
| 2019-12-31 | ILA22.20 | ILA5138.00 | x |
| 2020-12-31 | ILA41.57 | ILA5138.00 | x |
| 2021-12-31 | ILA51.02 | ILA5138.00 | x |
| 2022-12-31 | ILA54.36 | ILA5138.00 | x |
| 2023-12-31 | ILA55.72 | ILA5138.00 | x |
| 2024-12-31 | ILA57.87 | ILA5138.00 | x |
| 2025-12-31 | ILA61.07 | ILA5138.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ilex Medical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.11%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.97%
- • Asset Turnover: 0.94x
- • Equity Multiplier: 1.45x
- Recent ROE (8.11%) is below the historical average (18.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 17.00% | 8.75% | 1.25x | 1.55x | ILA7.67 Million |
| 2009 | 23.66% | 12.30% | 1.27x | 1.52x | ILA17.39 Million |
| 2010 | 23.88% | 11.67% | 1.29x | 1.59x | ILA16.77 Million |
| 2011 | 23.36% | 7.60% | 0.63x | 4.91x | ILA18.71 Million |
| 2013 | -25.66% | -4.81% | 0.86x | 6.17x | ILA-30.87 Million |
| 2014 | 24.05% | 5.11% | 0.85x | 5.51x | ILA12.91 Million |
| 2015 | 25.99% | 6.25% | 1.03x | 4.02x | ILA19.14 Million |
| 2016 | 19.60% | 5.33% | 1.06x | 3.46x | ILA13.54 Million |
| 2017 | 23.04% | 6.76% | 1.14x | 2.99x | ILA21.17 Million |
| 2018 | 24.75% | 7.82% | 1.13x | 2.81x | ILA28.00 Million |
| 2019 | 27.05% | 9.50% | 1.09x | 2.61x | ILA37.98 Million |
| 2020 | 27.20% | 12.74% | 1.21x | 1.76x | ILA76.27 Million |
| 2021 | 34.31% | 18.61% | 1.21x | 1.52x | ILA139.92 Million |
| 2022 | 16.66% | 11.70% | 0.97x | 1.47x | ILA40.81 Million |
| 2023 | 8.16% | 5.47% | 0.92x | 1.63x | ILA-11.47 Million |
| 2024 | 6.03% | 4.24% | 0.93x | 1.54x | ILA-25.67 Million |
| 2025 | 8.11% | 5.97% | 0.94x | 1.45x | ILA-12.92 Million |
Industry Comparison
This section compares Ilex Medical's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $49,851,778
- Average return on equity (ROE) among peers: -134.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ilex Medical (ILX) | ILA666.36 Million | 17.00% | 0.46x | $154.11 Million |
| Allmed Solutions Ltd (ALMD) | $52.31 Million | 5.37% | 0.05x | $7.99 Million |
| Erika Carmel Ltd (BCUR) | $42.67 Million | -76.32% | 0.60x | $4.69 Million |
| Bio-View Ltd (BIOV) | $16.69 Million | 8.64% | 0.79x | $20.36 Million |
| Brainsway Ltd (BWAY) | $15.58 Million | -42.02% | 0.65x | $422.69 Million |
| Erech Finance Cahalacha Ltd (EFNC) | $5.09 Million | -929.49% | 1.72x | $1.14 Million |
| Epitomee Medical Ltd (EPIT) | $3.98 Million | -79.63% | 4.36x | $32.37 Million |
| Erika Carmel-Tech Ltd (ERKA) | $9.79 Million | -59.80% | 1.98x | $4.98 Million |
| Human Xtensions Ltd (HUMX) | $148.82 Million | -19.18% | 0.12x | $2.12 Million |
| Pulsenmore Ltd (PULS) | $153.73 Million | -16.67% | 0.09x | $22.89 Million |
About Ilex Medical
Ilex Medical Ltd engages in the import, marketing, distribution and sale of medical laboratory equipment and various diagnostic products, diagnostic systems, and kits and consumables in Israel, the United States, and internationally. The company also provides laboratory services, as well as is involved in the development, production, marketing and sale of software systems for information manageme… Read more